Abstract

Background: Multiple myeloma (MM) is a bone marrow malignant plasma cell disease characterized by focal bone lesions, soft tissue lesions and diffuses bone marrow infiltration. The purpose of this study is to observe and analyze the value of serum lncRNACRNDE - H and GAS5 in predicting the prognosis of MM.

Methods: 80 cases of MM patients admitted from our hospital from December 2009 to December 2010 were selected for this study. All MM patients enrolled were treated with 4 courses of PAD program induction therapy. The follow-up was conducted for 4 years by telephone follow-up and follow-up visit patients, and the overall survival (OS) and progression free survival (PFS) of the patients were observed and compared.

Results: The difference between OS and PFS in the two subgroups was statistically significant (χ2=7.876-7.009, P<0.05). For patients with GAS5 low-expression and GAS5 high-expression, the OS estimated values were 34.030 months and 23.546 months respectively, 95 CI of (28.717-39.343) months and (19.270-27.823) month, PFS estimated values of 26.794 months and 19.753 montsh, 95% CI of (22.255-31.333) months and (15.897-23.609) months.

Conclusion: High expression of serum lncRNACRNDE- h is associated with poor prognosis in patients with MM. The level of serum lncRNACRNDE- h can be used as an auxiliary marker to predict the prognosis of patients with MM.